Acute lower limb ischemia caused by vaccine-induced immune thrombotic thrombocytopenia: focus on perioperative considerations for 2 cases.
Arterial thrombosis
Heparin-induced thrombocytopenia
Limb ischemia
Perioperative care
Vaccine-induced immune thrombotic thrombocytopenia
Journal
Thrombosis journal
ISSN: 1477-9560
Titre abrégé: Thromb J
Pays: England
ID NLM: 101170542
Informations de publication
Date de publication:
04 Jul 2022
04 Jul 2022
Historique:
received:
22
12
2021
accepted:
27
06
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
ChAdOx1 nCoV-19 (AstraZeneca) and Ad26COV2.S (Johnson & Johnson/Janssen) adenoviral vector vaccines have been associated with vaccine-induced immune thrombotic thrombocytopenia (VITT). Arterial thrombosis and acute limb ischemia have been described in a minority of patients with VITT. These patients usually need a revascularization, but they potentially are at a higher risk of complications. Optimal perioperative care of patients undergoing vascular surgery in acute VITT is unknown and important considerations in such context need to be described. We report 2 cases of VITT presenting with acute limb ischemia who needed vascular surgery and we describe the multidisciplinary team decisions for specific treatment surrounding the interventions. Both patients' platelet counts initially increased after either intravenous immune globulin (IVIG) or therapeutic plasma exchange (TPE). None received platelet transfusion. They both received argatroban as an alternative to heparin for their surgery. Despite persistent positivity of anti-platelet factor 4 (PF4) antibodies and serotonin-release assay with added PF4 (PF4-SRA) in both patients, only one received a repeated dose of IVIG before the intervention. Per- and post-operative courses were both unremarkable. In spite of persistent anti-PF4 and PF4-SRA positivity in the setting of VITT, after platelet count improvement using either IVIG or TPE, vascular interventions using argatroban can show favorable courses. Use of repeated IVIG or TPE before such interventions still needs to be defined.
Sections du résumé
BACKGROUND
BACKGROUND
ChAdOx1 nCoV-19 (AstraZeneca) and Ad26COV2.S (Johnson & Johnson/Janssen) adenoviral vector vaccines have been associated with vaccine-induced immune thrombotic thrombocytopenia (VITT). Arterial thrombosis and acute limb ischemia have been described in a minority of patients with VITT. These patients usually need a revascularization, but they potentially are at a higher risk of complications. Optimal perioperative care of patients undergoing vascular surgery in acute VITT is unknown and important considerations in such context need to be described.
CASES PRESENTATIONS
METHODS
We report 2 cases of VITT presenting with acute limb ischemia who needed vascular surgery and we describe the multidisciplinary team decisions for specific treatment surrounding the interventions. Both patients' platelet counts initially increased after either intravenous immune globulin (IVIG) or therapeutic plasma exchange (TPE). None received platelet transfusion. They both received argatroban as an alternative to heparin for their surgery. Despite persistent positivity of anti-platelet factor 4 (PF4) antibodies and serotonin-release assay with added PF4 (PF4-SRA) in both patients, only one received a repeated dose of IVIG before the intervention. Per- and post-operative courses were both unremarkable.
CONCLUSION
CONCLUSIONS
In spite of persistent anti-PF4 and PF4-SRA positivity in the setting of VITT, after platelet count improvement using either IVIG or TPE, vascular interventions using argatroban can show favorable courses. Use of repeated IVIG or TPE before such interventions still needs to be defined.
Identifiants
pubmed: 35787808
doi: 10.1186/s12959-022-00398-8
pii: 10.1186/s12959-022-00398-8
pmc: PMC9251912
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38Informations de copyright
© 2022. The Author(s).
Références
Blood. 2021 Jul 29;138(4):350-353
pubmed: 34323939
J Thromb Thrombolysis. 2020 Oct;50(3):674-677
pubmed: 32056070
Thromb Res. 2021 May;201:6-14
pubmed: 33621860
N Engl J Med. 2019 Sep 5;381(10):945-955
pubmed: 31483965
Blood Adv. 2018 Nov 27;2(22):3360-3392
pubmed: 30482768
Thromb Haemost. 2005 Jul;94(1):132-5
pubmed: 16113796
Transfusion. 2020 Nov;60(11):2714-2736
pubmed: 32812222
J Thromb Haemost. 2012 Jan;10(1):148-50
pubmed: 22018307
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
J Thromb Haemost. 2021 Jun;19(6):1585-1588
pubmed: 34018298
N Engl J Med. 2018 May 10;378(19):1845-1848
pubmed: 29742374
Ann Pharmacother. 2021 Feb;55(2):198-215
pubmed: 32693627
Platelets. 2017 Sep;28(6):614-620
pubmed: 28856946
Can J Anaesth. 2002 Jun-Jul;49(6):S36-49
pubmed: 12557413
Am J Health Syst Pharm. 2012 Mar 15;69(6):490-5
pubmed: 22382479
Pharmacotherapy. 2019 Aug;39(8):837-853
pubmed: 31233222
J Thromb Haemost. 2019 Nov;17(11):1956-1965
pubmed: 31350937
N Engl J Med. 2021 Oct 28;385(18):1680-1689
pubmed: 34379914
Am J Med. 1996 Nov;101(5):502-7
pubmed: 8948273
N Engl J Med. 2021 May 20;384(20):1964-1965
pubmed: 33852795
N Engl J Med. 2021 Aug 26;385(9):857-859
pubmed: 34233107
Ann Surg. 1983 Sep;198(3):301-6
pubmed: 6615052
N Engl J Med. 2021 Aug 19;385(8):720-728
pubmed: 34107198
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Blood. 2015 Jan 1;125(1):195-8
pubmed: 25406354
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
CMAJ. 2021 Jun 14;193(24):E906-E910
pubmed: 33990339
Blood. 2015 Feb 26;125(9):1470-6
pubmed: 25588677